World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial

Key Points:

• Australian researchers have developed the first personalized mRNA cancer vaccine that, in a phase 3 clinical trial, reduced the risk of melanoma recurrence or death by 42% when combined with standard immunotherapy.
• The vaccine, created by Moderna and Merck, uses tumor sequencing to generate a personalized immune "wanted poster," helping the immune system target cancer cells more effectively alongside the immunotherapy drug pembrolizumab.
• The phase 3 trial involved over 1,100 patients globally and showed even greater benefits for those cancer-free six months after treatment, with a 58% reduction in melanoma recurrence or death compared to pembrolizumab alone.
• Although not yet available to patients, the vaccine is undergoing regulatory review, offering hope especially in Australia, where melanoma rates are high and the vaccine could significantly reduce mortality.
• Experts see this breakthrough as a potential paradigm shift in cancer treatment, with personalized mRNA vaccines possibly improving outcomes for other cancers, despite recent mixed trial results in colorectal and head and neck cancers.